Related Experiment Video
Updated: Oct 27, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Statins for Prostate Cancer: When and How Much?
Teemu J Murtola1,2, Aino Siltari3,4
1Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. teemu.murtola@tuni.fi.
Low-dose atorvastatin did not reduce prostate cancer relapses in Asian men post-surgery. Further research is needed on higher statin doses and later disease stages for survival benefits.
Area of Science:
- Oncology
- Pharmacology
Background:
- Statins exhibit potential anti-prostate cancer properties.
- Previous research suggests a link between statin use and reduced prostate cancer mortality.
Purpose of the Study:
- To evaluate the efficacy of low-dose atorvastatin in preventing cancer relapse after radical prostatectomy.
- To assess the impact of statin therapy on disease recurrence in Asian men.
Main Methods:
- A randomized, placebo-controlled trial was conducted.
- Participants were Asian men who underwent radical prostatectomy.
- Low-dose atorvastatin was administered and compared to a placebo.
Main Results:
- No significant difference in relapse rates was observed between the atorvastatin and placebo groups.
- Low-dose atorvastatin did not demonstrate a benefit in preventing prostate cancer recurrence in this cohort.
Conclusions:
- Low-dose atorvastatin is not effective in reducing relapses after radical prostatectomy in Asian men.
- Future clinical trials should investigate higher statin doses and survival endpoints in later stages of prostate cancer.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Urinary Tract Calculi III: Medical Management

